Quzyttir (cetirizine hydrochloride) NDC 68118-200

NDC codes

FDA NDC Directory

Product NDC (as listed)68118-200Labeler and product segments. Claims need a package NDC.

Product NDC at billing width68118-0200Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
68118-200-10	68118020010	1 VIAL, GLASS in 1 CARTON (68118-200-10) / 1 mL in 1 VIAL, GLASS (68118-200-01)Marketed from Apr 2, 2020
68118-200-25	68118020025	25 VIAL, GLASS in 1 CARTON (68118-200-25) / 1 mL in 1 VIAL, GLASS (68118-200-01)Marketed from Nov 13, 2019

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Quzyttir
Generic name (nonproprietary): cetirizine hydrochloride
Active ingredients: Cetirizine hydrochloride — 10 mg/mL
Dosage form: Injection
Route: Intravenous
Labeler: ESTEVE PHARMACEUTICALS, S.A.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 211415
Marketing start: Nov 13, 2019
Listing expires: Dec 31, 2027
Other FDA classes: Histamine H1 Receptor Antagonists (Mechanism)
Identifiers: Product ID 68118-200_58f0707f-577d-c820-e063-6294a90ac2ceSPL ID 58f0707f-577d-c820-e063-6294a90ac2ceSPL set ID 573770f6-b76e-f6ba-e063-6294a90aa54dRxCUI 2261746, 2261754UNII 64O047KTOAUPC 0368118200102
Pharmacologic class: Histamine-1 Receptor Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N468118020010 followed by a unit qualifier and the quantity

Package 68118-0200-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 13, 2026.

Indications (excerpt from the label)

QUZYTTIR ® is indicated for the treatment of acute urticaria in adults and children 6 months of age and older. QUZYTTIR ® is a histamine-1 (H 1 ) receptor antagonist indicated for the treatment of acute urticaria in adults and children 6 months of age and older ( 1 ) Limitations of Use : Not recommended in pediatric patients less than 6 years of age with impaired renal or hepatic function ( 1 ) Limitations of use: QUZYTTIR ® is not recommended in pediatric patients less than 6 years of age with impaired renal or hepatic function.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 211415

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 211415
Product	Strength	Form · route	Labeler	Product NDC
Quzyttircetirizine hydrochloride	Cetirizine hydrochloride 10 mg/mL	InjectionIntravenous	TerSera Therapeutics LLC	70720-100